Nanjing Genscript Biotech Co., Ltd.

Nanjing Legend Biotech Co., Ltd.

Liusong Yin

Zhuo Fang

Tielin Zhou

Chunchen Wu

Yanling Mi

Chuan-Chu Chou

Shu Wu

Shuai Yang

Bo Wu

Qiuchuan Zhuang

Zhongdao Li

Feng Lin

Dan Zhao

Xinpo Jiang

Qingshan Zhang

Yong Liu

Xiaohu Fan

Jie Mao

The present invention relates to an anti-CD47/anti-PD-1 bispecific antibody, preparation method thereof and use thereof. The bispecific antibody includes (a) a first antigen binding portion including a heavy chain variable region (Vn) and a light chain variable region (Vl), wherein Vn and Vl form an antigen binding site that specifically binds to CD47; and (b) a second antigen binding portion including a single-domain antibody (sdAb) that specifically binds to PD-1, wherein the first antigen binding portion and the second antigen binding portion are fused with each other. The bispecific antibody of the present invention can block two manners of tumor immune escape simultaneously, and thus, has a good effect in tumor immunotherapy.

Anti-CD47/anti-PD-1 bispecific antibody, preparation method and use thereof

The present invention relates to a humanized anti-human OX40 monoclonal antibody, and a preparation method and use thereof. The humanized anti-human OX40 monoclonal antibody provided in the present invention has high affinity and specificity for OX40, and can stimulate T cells to secrete cytokines, for example, specifically activate the positive immune regulation by OX40 and activate T cells to secrete cytokines. Therefore, the functional humanized anti-human OX40 monoclonal antibody provided in the present invention activates T cells by activating the OX40 signaling pathway, thereby achieving the purpose of tumor immunotherapy.

Humanized anti-human OX40 monoclonal antibody, preparation method therefor and use thereof

Described herein are binding moieties, such as antibodies, that specifically bind Claudin18.2, and chimeric antigen receptors comprising such binding moieties. Further provided are engineered immune cells (such as T cells) comprising anti-Claudin 18.2 chimeric antigen receptors. Also disclosed are methods of treating Claudin18.2-expressing tumor or cancers using the binding moieties, chimeric antigen receptors and engineered immune cells.

Claudin18.2 binding moieties and uses thereof

The present application provides an antibody, such as a monoclonal antibody (mAb), or an antigen binding fragment thereof, that specifically recognizes PD-L1. Also provided are pharmaceutical compositions, or methods of making and using the antibody or antigen binding fragment thereof.

Antibodies and variants thereof against PD-L1

The present invention relates to a humanized anti-human PD-L1 monoclonal antibody, and a preparation method and use thereof. The humanized anti-human PD-L1 monoclonal antibody provided in the present invention has high affinity and specificity for PD-L1, stimulates T cells to secrete cytokines, and specifically relieves the negative immune regulation by PD-L1. The effect of this antibody is not achieved by directly blocking the interaction between PD-1 and PD-L1, presenting a new mechanism of immune checkpoint regulation. Therefore, the functional humanized anti-human PD-L1 monoclonal antibody provided in the present invention activates T cells by regulating the PD-L1 signaling pathway, thereby achieving the purpose of tumor immunotherapy.

Humanized anti-human PD-L1 monoclonal antibody and preparation method therefor and use thereof

The present invention relates to a humanized anti-human CTLA4 monoclonal antibody. The present invention also relates to a preparation method and application of the humanized anti-human CTLA4 monoclonal antibody.

Humanized anti-human CTLA4 monoclonal antibody, preparation method therefor and use thereof

Growing community of inventors

Jiangsu, China

Liusong Yin